Copyright
©The Author(s) 2005.
World J Gastroenterol. Sep 14, 2005; 11(34): 5283-5288
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5283
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5283
Figure 1 OS of total 49 HBV carriers’ undergoing chemotherapy for non-Hodgkin’s lymphoma, according to HBV reactivation status (P = 0.
601) (A); comparison of liver reserve between HBV reactivators and HBV non-reactivators (P = 0.0342) (B).
Figure 2 Relationship between genotype and liver cirrhosis in HBV reactivators (P = 0.
003).
Figure 3 OS in HBV reactivation patients with different reactivation patterns (P = 0.
000). (MA: multiple reactivations; PR: protracted/resolved; PU: protracted/ unresolved.).
- Citation: Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol 2005; 11(34): 5283-5288
- URL: https://www.wjgnet.com/1007-9327/full/v11/i34/5283.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i34.5283